MAZE - CIK 0001842295
The table below shows Maze Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 |
|---|---|---|---|
| Operating cash flow | -$39.11M | -$29.52M | -$23.44M |
| Capital expenditure | $93.00K | $299.00K | $279.00K |
| Investing cash flow | $6.28M | -$299.00K | -$279.00K |
| Dividends paid | - | - | - |
| Stock buybacks | - | - | - |
| Financing cash flow | $42.36M | $127.38M | $24.58M |
Maze Therapeutics, Inc. reported operating cash flow of -$111.94M for fiscal year 2025. That is down 247.4% from $75.95M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.